Ed Arce
Stock Analyst at WestPark Capital
(4.60)
# 188
Out of 5,179 analysts
376
Total ratings
46.96%
Success rate
47.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $12.18 | +129.89% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $27.25 | +10.09% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.22 | +10,719.67% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.39 | +1,073.71% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $6.76 | +787.57% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.34 | +459.70% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $5.75 | +126.09% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $2.68 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.74 | +709.17% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.66 | +951.05% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $27.70 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $3.76 | +6,282.98% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.17 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $4.89 | +554.40% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $88.44 | -18.59% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $510.68 | -20.69% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.48 | +0.36% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $19.38 | +390.20% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.29 | +16.55% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $29.98 | +60.11% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $52.92 | -85.83% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.04 | +13,944.94% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.27 | -8.90% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $38.86 | -35.67% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.50 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.58 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $32.52 | -78.47% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $32.44 | -35.27% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.12 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $12.18
Upside: +129.89%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $27.25
Upside: +10.09%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.22
Upside: +10,719.67%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.39
Upside: +1,073.71%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $6.76
Upside: +787.57%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.34
Upside: +459.70%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $5.75
Upside: +126.09%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.68
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.74
Upside: +709.17%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.66
Upside: +951.05%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $27.70
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $3.76
Upside: +6,282.98%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $4.89
Upside: +554.40%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $88.44
Upside: -18.59%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $510.68
Upside: -20.69%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.48
Upside: +0.36%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $19.38
Upside: +390.20%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.29
Upside: +16.55%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $29.98
Upside: +60.11%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $52.92
Upside: -85.83%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.04
Upside: +13,944.94%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.27
Upside: -8.90%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $38.86
Upside: -35.67%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.50
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.58
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $32.52
Upside: -78.47%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $32.44
Upside: -35.27%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.12
Upside: -